Thank you baldwidx, but I think perhaps you’re giving me far too much credit. I simply report on what other clever scientists have studied!
Also, perhaps not enough credit is being given to NEU management. I’m confident that the team at Neuren is very aware of the extensive therapeutic potential of NNZ-2591.
In addition to the rare paediatric neurodevelopmental disorders that are Neuren’s current focus for development of both trofinetide and NNZ-2591, the Company has made clear that both drugs could potentially address a range of other conditions.
These include TBI, stroke, Parkinson’s disease, MS, Alzheimer’s, Parkinson’s and peripheral neuropathy, in all of which preclinical testing has been completed, as well as FXTAS, cognitive impairment, anxiety, depression, schizophrenia, PTSD and, yes, also idiopathic autism.
Published research by others into IGF-1 suggests there could be even more therapeutic uses for NNZ-2591. These include diverse indications such as eye disease, cognitive decline following sleep deprivation and as a therapeutic intervention for those at risk of cardiovascular and cerebrovascular illness.
However, while all of this makes NNZ-2591 a very interesting molecule of great potential, the reality is that resources are limited and pharma deals reward great clinical data for a drug rather than potential.
Being conscious of this, I must admit I did think twice about posting on this research on the role of IGF-1 in idiopathic autism. But my interest and excitement about this hypothesis of biphasic dysregulation of IGF-1 in idiopathic autism during the early years made me curious as to whether anyone else on the forum had come across this theory before.
Neuren is now testing NNZ-2591 in the very early age group from birth in HIE but in age 3+ in the various genetic neurodevelopmental disorders, where the aim is symptomatic treatment. My thought was, if biphasic dysregulation of IGF-1 in the first few years of life does indeed contribute to the development of idiopathic autism, could therapeutic intervention with IGF-1 regulating-NNZ-2591 during this early stage of development potentially strongly alter or even prevent the progression of this disorder?
NEU Price at posting:
$13.76 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)